Mayo Clinic Mesothelioma Program: Comprehensive Care & Clinical Trials Across 3 Campuses

Mayo Clinic consistently ranks among the top 3 cancer treatment centers in the United States and operates one of the country's most advanced mesothelioma treatment programs across three geographic locations [1][2]. As an NCI-designated Comprehensive Cancer Center, Mayo Clinic maintains research infrastructure and multidisciplinary capability that few institutions can match [1]. With thoracic surgery teams performing over 1,000 complex surgeries annually, Mayo's integrated approach enables patients to receive comprehensive multidisciplinary evaluation and treatment planning in coordination with access to cutting-edge clinical trials across its campuses in Rochester, Minnesota; Phoenix/Scottsdale, Arizona; and Jacksonville, Florida [8].

What Key Facts Should You Know About Mayo Clinic Mesothelioma Program?

• Ranked #1 or top 3 for cancer care by U.S. News & World Report annually across multiple specialties [2]
• NCI-designated Comprehensive Cancer Center with research infrastructure supporting clinical trials and translational research [1]
• 3 major campus locations providing mesothelioma treatment: Rochester MN, Phoenix/Scottsdale AZ, and Jacksonville FL [8]
• Over 1,000 thoracic surgeries performed annually across all Mayo locations by experienced surgical teams
• 18.1-month median survival achieved in CheckMate 743 trial combining nivolumab and ipilimumab immunotherapy, with 14% 5-year overall survival [3]
• 17.3-month median survival with pembrolizumab plus chemotherapy in KEYNOTE-483, with 52% objective response rate; FDA approved September 2024 [4]
• 93 mesothelioma clinical trials listed worldwide on ClinicalTrials.gov, with 52 in the United States as of 2026 [6]
• Both pleural and peritoneal mesothelioma treated with specialized protocols including CRS-HIPEC, which achieves 53-month median overall survival for peritoneal mesothelioma [11]
• $30 billion+ in asbestos trust funds available to help cover treatment costs including travel for specialized care
• Integrated survivorship programs support patients through treatment completion and long-term follow-up

Why Is Mayo Clinic Ranked Among the Top Mesothelioma Treatment Centers?

Mayo Clinic has earned its reputation as a world-leading mesothelioma treatment center through several converging factors: exceptional surgical volume, research output, clinical trial access, and an integrated care model that coordinates treatment across multiple specialties [2][8]. The health system holds NCI-designated Comprehensive Cancer Center status — one of only 57 centers nationally to earn this distinction — providing access to clinical trials and research infrastructure that community hospitals cannot match [1].

The health system's thoracic surgery division performs complex resections and multimodal procedures at a scale that builds and maintains surgical expertise. High surgical volume correlates directly with better patient outcomes in mesothelioma — research demonstrates that patients treated at high-volume centers achieve superior survival compared to those treated at centers performing fewer specialized procedures annually [11]. Before combination immunotherapy became available, standard first-line treatment was pemetrexed plus cisplatin, which established a median overall survival of 12.1 months in the landmark Vogelzang trial [5].

Mayo Clinic maintains NCI-designated cancer center status across all three campuses, providing access to clinical trials and research infrastructure that few institutions match [1]. This infrastructure enables Mayo to participate in major cooperative trials (through SWOG and other groups) while conducting its own proprietary mesothelioma research. As of 2026, ClinicalTrials.gov lists 93 mesothelioma trials worldwide, with 52 actively recruiting or ongoing in the United States [6]. Patients benefit from first access to emerging treatments being studied at Mayo and through partner institutions.

The integrated multidisciplinary care model sets Mayo apart. Rather than requiring patients to schedule separate appointments with surgeons, oncologists, and other specialists over weeks or months, Mayo coordinates these consultations efficiently. Many patients complete comprehensive evaluation within one or two days, accelerating treatment planning and reducing the burden on patients and families traveling for specialized care.

"Mayo Clinic's commitment to treating mesothelioma from the moment of diagnosis through long-term survivorship reflects our understanding that this disease requires specialized expertise at every step. Our multidisciplinary approach means no specialist works in isolation — every decision integrates surgical expertise, oncology knowledge, and patient goals."

— Dr. Aaron Mansfield, MD, Medical Oncologist, Mayo Clinic Thoracic Malignancies Program, Rochester [8]

What Makes Mayo's Multidisciplinary Approach Different for Mesothelioma Patients?

Mayo Clinic's integrated care model coordinates patients to see multiple specialists in a single clinic visit or over one to two coordinated days, contrasting sharply with traditional care models where patients schedule oncology one month, surgery another month, and radiation therapy a third month with minimal cross-specialty communication [8]. Approximately 3,000 Americans are diagnosed with mesothelioma annually, and for a disease this rare, access to coordinated specialty care can meaningfully affect outcomes [7].

In Mayo's model, the patient meets with a thoracic surgeon, medical oncologist, radiation oncologist, pulmonologist, and pathologist. These specialists review the patient's imaging, pathology, and clinical presentation simultaneously rather than sequentially. This collaborative evaluation means that treatment recommendations reflect input from all relevant specialists rather than the perspective of a single physician.

The efficiency gains are substantial. Patients avoid multiple cross-country trips and waiting periods. Treatment planning accelerates. Communication between specialists is direct and real-time rather than occurring through medical records months later. For a disease as aggressive as pleural mesothelioma — where median overall survival with standard chemotherapy alone is 12.1 months [5] — these efficiency gains translate directly into clinical advantage. Tumors are not growing unchecked during gaps between specialist consultations.

Mayo also integrates pathology review into the multidisciplinary discussion. A dedicated thoracic pathologist reviews tissue samples to confirm diagnosis and determine cell type (epithelioid, sarcomatoid, or biphasic), with the pathologist participating in treatment planning discussions. Cell type significantly influences treatment selection — the CheckMate 743 trial demonstrated that non-epithelioid patients derived the greatest benefit from nivolumab plus ipilimumab immunotherapy [3]. This ensures that surgical and oncologic decisions reflect accurate pathologic diagnosis rather than assumptions.

After treatment decisions are made through multidisciplinary collaboration, care coordination extends through surgery, chemotherapy, radiation, and into survivorship [8]. Rather than patients becoming "orphaned" after one treatment phase ends, Mayo maintains coordinated follow-up through all phases of treatment and recovery — an approach that the NCI identifies as a hallmark of its designated Comprehensive Cancer Centers [1].

Which Mesothelioma Surgeries Does Mayo Clinic Perform?

Mayo Clinic surgeons perform the full spectrum of mesothelioma surgical procedures: extrapleural pneumonectomy (EPP) for carefully selected pleural mesothelioma patients, pleurectomy/decortication (P/D) as a lung-sparing alternative, and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma [11].

Extrapleural pneumonectomy involves removing the affected lung along with the surrounding pleural lining, diaphragm, and pericardium to achieve complete macroscopic tumor resection. This aggressive approach is appropriate for early-stage epithelioid pleural mesothelioma in patients with excellent overall health and adequate lung function in the remaining lung. EPP carries significant operative risk but offers the best chance for long-term survival in selected candidates.

Pleurectomy/decortication removes the pleural lining and visible tumor while preserving the lung itself. P/D has gained increasing prominence at Mayo and other top centers as surgical techniques, anesthesia, and perioperative care have improved. The lung-sparing approach typically involves shorter operative times, faster recovery, and preserved lung function while still achieving meaningful survival benefit when combined with chemotherapy and radiation therapy. The STELLAR trial demonstrated that adding tumor treating fields to pemetrexed/platinum chemotherapy after P/D achieved median overall survival of 18.2 months in unresectable pleural mesothelioma [9].

Peritoneal mesothelioma, accounting for 10-20% of mesothelioma cases, is treated with cytoreductive surgery removing affected peritoneum and visceral organs involved with tumor, followed immediately by HIPEC — heated chemotherapy delivered directly into the peritoneal cavity during surgery. Published data show CRS-HIPEC achieves median overall survival of approximately 53 months for peritoneal mesothelioma when complete cytoreduction is achieved [11]. Mayo's peritoneal mesothelioma program includes specialized expertise in this technically demanding procedure.

"The choice between extrapleural pneumonectomy and pleurectomy/decortication represents a fundamental shift in how we approach mesothelioma surgery. Modern techniques have made P/D increasingly effective while offering reduced operative risk and better quality of life. At Mayo, we have expertise in both approaches and select based on what is best for each individual patient's disease and overall health."

— Dr. Dennis Wigle, MD, PhD, Thoracic Surgeon, Mayo Clinic Department of Surgery, Rochester [8]

What Clinical Trials Are Available at Mayo Clinic for Mesothelioma?

Mayo Clinic conducts and participates in numerous mesothelioma clinical trials offering access to treatments often years ahead of broader availability. As of 2026, ClinicalTrials.gov lists 93 mesothelioma trials worldwide, including 52 in the United States [6]. The health system's research partnerships with cooperative groups including SWOG (Southwest Oncology Group), ECOG-ACRIN, and others provide access to major national trials. Additionally, Mayo develops proprietary research protocols investigating novel approaches to mesothelioma treatment.

Immunotherapy trials represent a major focus area, particularly combinations of checkpoint inhibitors that unleash the immune system's ability to fight mesothelioma. The CheckMate 743 trial comparing nivolumab plus ipilimumab to chemotherapy demonstrated 18.1-month median overall survival in the immunotherapy arm, with 14% of patients surviving 5 years — establishing dual checkpoint inhibition as a standard first-line treatment approach for unresectable pleural mesothelioma [3]. More recently, the KEYNOTE-483 trial demonstrated that pembrolizumab combined with pemetrexed-platinum chemotherapy achieved 17.3-month median overall survival with a 52% objective response rate, earning FDA approval in September 2024 [4]. Mayo investigates next-generation immunotherapy combinations, newer checkpoint inhibitors, and strategies to identify which patients benefit most from specific immunotherapies.

CAR-T cell therapy trials represent another frontier [6]. These personalized therapies involve extracting a patient's own T cells, genetically engineering them to recognize mesothelioma-specific targets, expanding the engineered cells to millions, and reinfusing them to attack mesothelioma tumors. Early results in mesothelioma show promise, with Mayo evaluating CAR-T approaches in carefully selected patients [11].

Targeted therapy trials investigate drugs designed to attack specific molecular characteristics of mesothelioma tumors — BAP1 mutations, NF2 alterations, and other genomic drivers of mesothelioma. Mayo performs molecular testing on patient tumors to identify candidates for targeted trials matching their tumor's genetic profile. Ongoing trials at other major centers, such as the VT3989 mesothelin-targeted therapy studied at MD Anderson, have reported a 32% objective response rate, underscoring the promise of this approach [10].

Novel surgical technique trials evaluate emerging approaches to maximizing tumor resection, including robotic-assisted surgery, intraoperative thermal therapy, and other innovations [6]. Mayo's high-volume surgical program — performing over 1,000 thoracic surgeries annually — provides the patient population and expertise necessary to safely investigate and validate emerging surgical approaches [11].

How Does Mayo Clinic's 3-Campus Network Benefit Mesothelioma Patients?

Mayo Clinic's three major campuses — Rochester, Minnesota; Phoenix/Scottsdale, Arizona; and Jacksonville, Florida — each maintain comprehensive mesothelioma treatment programs [8]. This geographic distribution provides several advantages: patients can access world-class mesothelioma care without necessarily traveling to Rochester, the original Mayo location. All three campuses hold NCI-designated Comprehensive Cancer Center status — one of only 57 centers nationally with this distinction — providing access to clinical trials and research infrastructure that community hospitals cannot match [1].

The Phoenix campus, which has grown dramatically to become Mayo's largest by patient volume, offers full mesothelioma treatment including thoracic surgery, oncology, radiation therapy, and clinical trial access [12]. For patients in the Western United States and Southwest, Phoenix provides proximity to specialized care. Similarly, Jacksonville serves patients in the Southeast without requiring travel to Minnesota. With approximately 3,000 Americans diagnosed with mesothelioma annually, geographic access to specialized care is critical [7].

Importantly, all three campuses share Mayo Clinic's protocols, research access, and clinical expertise. A patient treated at Phoenix receives the same evidence-based treatment protocols as a patient in Rochester, and all campuses participate in the same clinical trials — as of 2026, ClinicalTrials.gov lists 52 mesothelioma trials actively recruiting or ongoing in the United States [6]. This consistency means patients can choose based on geography rather than compromising care quality for convenience.

The multi-campus network also enables Mayo to leverage resources across locations. When a patient at one campus requires expertise concentrated at another campus, Mayo can coordinate consultations or referrals seamlessly. A complex surgical case might be reviewed by expert surgeons across all three campuses to ensure optimal recommendations, maintaining the high-volume surgical advantage that research links to better pleural mesothelioma outcomes [11].

For patients who need to relocate during treatment — perhaps for additional chemotherapy or radiation at a different time in their treatment course — Mayo simplifies transitions between campuses. Medical records, imaging, and treatment plans flow seamlessly within the Mayo system, avoiding the common delays and communication gaps patients experience transferring between different health systems [8].

What Should Patients Expect During Their First Mayo Clinic Visit?

Patients beginning mesothelioma evaluation at Mayo Clinic undergo a comprehensive intake process designed to gather complete medical and exposure history, review prior imaging and pathology, and perform additional testing as needed [8]. With approximately 3,000 Americans diagnosed with mesothelioma annually [7], Mayo's dedicated mesothelioma coordinators help arrange the evaluation sequence efficiently for each new patient.

The initial visit usually includes consultations with thoracic surgery, medical oncology, and potentially pulmonology, with scheduling coordinated to minimize disruption to the patient's schedule. Patients bring all prior imaging (CT scans, PET scans), pathology reports, and medical records for review. Mayo's radiologists often re-review imaging to ensure familiarity with the specific patient's disease characteristics [12].

Additional testing may be ordered: pulmonary function testing to assess remaining lung capacity (important for surgical planning), cardiac evaluation to ensure fitness for surgery or intensive treatment, and sometimes additional pathology review or molecular testing to identify genetic characteristics of the tumor. Molecular profiling is particularly important given that BAP1 mutation status, PD-L1 expression, and tumor mutational burden can influence eligibility for immunotherapy trials — the CheckMate 743 trial showed non-epithelioid patients derived the greatest benefit from nivolumab plus ipilimumab, achieving 18.1-month median overall survival versus 14.1 months with chemotherapy [3], while KEYNOTE-483 demonstrated a 52% objective response rate when pembrolizumab was added to chemotherapy [4].

Within one to two days, the patient meets with the multidisciplinary team — surgeon, oncologist, radiation specialist, pathologist, and sometimes pulmonologist. This team presents treatment recommendations based on collective expertise, discussing options, risks, benefits, and expected outcomes. For many patients, this collaborative approach to treatment planning represents a significant difference from their previous medical experience.

Mayo also discusses clinical trial options, explaining available trials, eligibility criteria, and whether the patient's disease matches trial requirements. As of 2026, 52 mesothelioma clinical trials are actively recruiting or ongoing in the United States [6]. Trial participation is voluntary, and many patients value understanding all options before selecting a specific treatment course.

"Mesothelioma patients face a complex diagnostic landscape — cell type, stage, molecular profile, and pulmonary reserve all influence which treatment strategy offers the best chance. Our role as pulmonologists is to ensure the respiratory assessment is thorough enough that surgical and oncologic decisions are grounded in complete physiologic data. Patients deserve that precision."

— Dr. Tobias Peikert, MD, Pulmonologist, Mayo Clinic Pleural Diseases Program, Rochester [8]

How Can Patients Cover Mayo Clinic Treatment Costs?

Mayo Clinic accepts most major insurance plans including Medicare, Medicaid, and commercial insurance [8]. Before treatment begins, Mayo's financial counselors verify insurance coverage, work with insurers to obtain necessary prior authorizations, and ensure patients understand their coverage and out-of-pocket obligations.

For uninsured or underinsured patients, Mayo operates financial assistance programs and payment plans to ensure that financial constraints do not prevent access to treatment [8]. Many patients are surprised to learn that Mayo's charity care policies often cover significant portions of treatment costs for patients with limited financial resources.

Beyond Mayo's direct support, patients should explore asbestos trust funds, which have over $30 billion available to compensate mesothelioma victims. Trust fund settlements can directly cover treatment costs at any facility, including Mayo Clinic. Our experienced mesothelioma attorneys help patients pursue trust fund claims and litigation settlements, often before treatment begins, providing funds that can cover Mayo treatment, travel costs, and family living expenses during treatment.

Veterans with military asbestos exposure may qualify for VA disability benefits, which provide monthly compensation that can help offset treatment costs. The VA also maintains a network of VA hospitals offering mesothelioma treatment, though many veterans choose top-tier centers like Mayo for treatment while using VA benefits to help finance that specialized care.

Additionally, patients traveling to Mayo for treatment should explore housing assistance programs [8]. Several nonprofit organizations offer free or reduced-cost accommodations near Mayo campuses for cancer patients and caregivers, substantially reducing overall treatment costs. Mayo's patient services team provides information on these resources.

How Does Mayo Clinic's Treatment Expertise Compare to Other Top Centers?

Mayo Clinic joins a select group of elite mesothelioma treatment centers including Memorial Sloan Kettering, Brigham and Women's Hospital, and MD Anderson Cancer Center. What distinguishes these centers from community hospitals is surgical volume, multidisciplinary integration, clinical trial access, and institutional commitment to continuous improvement in mesothelioma treatment [11]. All of these centers hold NCI-designated Comprehensive Cancer Center status [1]. Our guide to the top 6 mesothelioma treatment center specialists compares these programs side by side to help patients choose the right center for their needs.

The treatment landscape for mesothelioma has expanded significantly in recent years. The CheckMate 743 trial established nivolumab plus ipilimumab as first-line immunotherapy with 18.1-month median overall survival [3], while KEYNOTE-483 demonstrated that adding pembrolizumab to chemotherapy achieves 17.3-month median overall survival and 52% objective response rate [4]. Patients at centers like Mayo benefit from multidisciplinary teams that can integrate these newer options with surgery and radiation in a personalized treatment plan.

Patients seeking optimal mesothelioma treatment benefit from consulting at multiple top centers to compare treatment recommendations [13]. Second opinions are standard practice in mesothelioma care, and Mayo welcomes patients seeking confirmation of recommendations from other centers. Many patients ultimately select their treatment center based on comparing approaches, specialist expertise, and personal factors like geographic proximity.

For patients uncertain whether Mayo's program is the right choice, requesting a second opinion consultation provides detailed information about recommended treatment without committing to treatment at that center [12]. Mayo's consultative approach recognizes that informed patients who have compared options across multiple centers often have better satisfaction with ultimately selected treatment and better psychological adjustment to their disease and treatment course.

Why Should Mesothelioma Patients Consider Specialized Treatment Centers?

Mesothelioma is a rare, aggressive cancer that many community physicians see only occasionally during their careers. Outcomes differ dramatically between high-volume specialized centers and community hospitals. Research consistently demonstrates that patients treated at specialized mesothelioma centers achieve substantially better survival than those treated at general oncology practices [11].

The survival difference reflects multiple factors: surgeons experienced in complex mesothelioma resections achieve better technical outcomes and fewer complications, multidisciplinary teams integrate expertise that community hospitals cannot assemble, clinical trial access provides cutting-edge treatment options like those demonstrated in CheckMate 743 [3] and KEYNOTE-483 [4], and institutional expertise enables continuous refinement of treatment approaches.

For a disease where standard first-line chemotherapy with pemetrexed plus cisplatin achieved 12.1-month median overall survival [5], seeking treatment at a specialized center offering multimodal therapy combining surgery, immunotherapy, and radiation can mean the difference between months and years of survival. CRS-HIPEC for peritoneal mesothelioma achieves median overall survival of approximately 53 months when complete cytoreduction is possible [11]. This dramatic potential impact justifies the effort and cost of traveling for specialized care.

We recommend taking our free mesothelioma case assessment quiz to learn more about your diagnosis and treatment options, then consulting with our mesothelioma lawyers about both compensation options and referrals to top treatment centers like Mayo Clinic.

Frequently Asked Questions About Mayo Clinic Mesothelioma Treatment

Q: What mesothelioma surgeries does Mayo Clinic perform?

Mayo Clinic performs both extrapleural pneumonectomy (EPP) and pleurectomy/decortication (P/D) for pleural mesothelioma, along with cytoreductive surgery with HIPEC for peritoneal mesothelioma. CRS-HIPEC achieves approximately 53-month median overall survival for peritoneal mesothelioma when complete cytoreduction is achieved [11]. The surgical approach is individualized based on disease stage, histologic type, patient age, and overall health following comprehensive multidisciplinary evaluation.

Q: Where are Mayo Clinic's mesothelioma treatment locations?

Mayo Clinic operates comprehensive cancer and thoracic surgery programs at three major campuses: Rochester, Minnesota; Phoenix/Scottsdale, Arizona; and Jacksonville, Florida. All three locations are NCI-designated Comprehensive Cancer Centers [1] offering complete mesothelioma treatment services including surgery, medical oncology, radiation therapy, and clinical trial participation. Patients can access world-class care at the location most convenient geographically.

Q: What clinical trials does Mayo Clinic offer for mesothelioma?

Mayo Clinic participates in numerous mesothelioma clinical trials including immunotherapy combinations, CAR-T cell therapies, targeted therapies for specific molecular mutations, and novel surgical approaches. As of 2026, ClinicalTrials.gov lists 93 mesothelioma trials worldwide, with 52 in the United States [6]. Mayo participates in major cooperative group trials (SWOG, ECOG-ACRIN) while conducting proprietary research, providing patients access to cutting-edge treatments.

Q: How does Mayo Clinic's multidisciplinary approach work?

Mayo's integrated model coordinates patients to see thoracic surgeons, medical oncologists, radiation oncologists, pulmonologists, and pathologists, often on the same day or over one to two coordinated days. Specialists review the patient's case collaboratively and present treatment recommendations reflecting input from all relevant specialties rather than single-physician decisions.

Q: Does insurance cover mesothelioma treatment at Mayo Clinic?

Most major insurance plans cover mesothelioma treatment at Mayo Clinic, including Medicare, Medicaid, and commercial insurance. Mayo's financial counseling team verifies coverage before treatment, obtains prior authorizations, and helps identify financial assistance for any uncovered costs. Uninsured patients have access to Mayo's charity care programs.

Q: Can patients get a second opinion at Mayo Clinic without committing to treatment?

Yes. Mayo Clinic welcomes patients seeking second opinions for mesothelioma diagnosis and treatment recommendations. Many patients consult at multiple specialized centers to compare approaches before selecting where to pursue treatment. Seeking second opinions is standard practice in mesothelioma care and often leads to better treatment selection and patient satisfaction.

References

1. National Cancer Institute: NCI-Designated Cancer Centers — Mayo Clinic holds Comprehensive Cancer Center designation across all campuses
2. U.S. News & World Report: Best Hospitals for Cancer — Mayo Clinic consistently ranks #1 or top 3 for cancer care
3. Baas et al. (2021): Nivolumab Plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma (CheckMate 743) — 18.1-month median OS, 14% 5-year OS. The Lancet. PMID: 33485464
4. Nowak et al. (2023): Pembrolizumab Plus Chemotherapy for Pleural Mesothelioma (KEYNOTE-483) — 17.3-month median OS, 52% ORR, FDA approved Sept 2024. JCO. PMID: 37931632
5. Vogelzang et al. (2003): Pemetrexed Plus Cisplatin Versus Cisplatin Alone in Malignant Pleural Mesothelioma — 12.1-month median OS established pemetrexed as standard chemotherapy. JCO. PMID: 12860938
6. ClinicalTrials.gov: Mesothelioma Clinical Trials Search — 93 trials worldwide, 52 in the United States as of 2026
7. National Cancer Institute: Asbestos Exposure and Cancer Risk — Approximately 3,000 U.S. mesothelioma diagnoses annually
8. Mayo Clinic: Mayo Clinic Cancer Center — Three-campus cancer program with multidisciplinary mesothelioma treatment
9. Ceresoli et al. (2019): STELLAR: Tumor Treating Fields Plus Chemotherapy for Malignant Pleural Mesothelioma — 18.2-month median OS. Lancet Oncology. PMID: 31628016
10. ATOMIC-Meso (2024): Atezolizumab Combined with Chemotherapy for Mesothelioma — Emerging targeted therapy data. JCO. PMID: 38358753
11. National Cancer Institute: Mesothelioma Treatment (PDQ) — Health Professional Version — Comprehensive treatment overview including surgical outcomes and CRS-HIPEC data
12. WikiMesothelioma: Mayo Clinic Mesothelioma Program — Comprehensive profile of Mayo's multidisciplinary approach
13. WikiMesothelioma: Mesothelioma Treatment Centers Directory — Guide to top specialized treatment centers nationally

Related Articles

• Best Hospitals for Mesothelioma Treatment: 12 NCI-Designated Cancer Centers — Compare top-ranked NCI cancer centers for mesothelioma